Catalyst Pharmaceuticals Files 8-K
Ticker: CPRX · Form: 8-K · Filed: May 30, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec
TL;DR
Catalyst Pharma filed a routine 8-K, no new info yet.
AI Summary
Catalyst Pharmaceuticals, Inc. filed an 8-K on May 30, 2024, to report other events and financial statements. The filing does not contain specific details on new events or financial figures but serves as a standard regulatory update.
Why It Matters
This filing indicates Catalyst Pharmaceuticals is meeting its regulatory reporting obligations with the SEC. It does not contain new material information for investors at this time.
Risk Assessment
Risk Level: low — The filing is a standard regulatory document and does not disclose any new material risks or events.
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- May 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 30, 2024.
What specific 'Other Events' are detailed in this filing?
The provided text of the 8-K filing does not detail specific 'Other Events'; it only indicates that this item is being reported.
Are there any new financial statements or exhibits included with this filing?
The filing indicates that 'Financial Statements and Exhibits' are being reported, but the specific content of these is not detailed in the provided header information.
When was Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?
The principal executive office address is 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.
Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-30 16:43:02
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d831301d8k.htm (8-K) — 24KB
- d831301dex991.htm (EX-99.1) — 10KB
- 0001193125-24-150433.txt ( ) — 157KB
- cprx-20240530.xsd (EX-101.SCH) — 3KB
- cprx-20240530_lab.xml (EX-101.LAB) — 18KB
- cprx-20240530_pre.xml (EX-101.PRE) — 11KB
- d831301d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on May 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: May 30, 2024 3